Brief: Simulations Plus Acquires Immunetrics To Expand Its Immunology And Oncology Drug Development Capabilities
20/06/2023 16:12
June 20 (Reuters) - Simulations Plus Inc SLP.O :
* SIMULATIONS PLUS ACQUIRES IMMUNETRICS TO EXPAND ITS
IMMUNOLOGY
AND ONCOLOGY DRUG DEVELOPMENT CAPABILITIES
* SIMULATIONS PLUS INC SAYS UNDER TERMS OF AGREEMENT, CO
AGREED TO
PAY SHAREHOLDERS OF IMMUNETRICS CASH CONSIDERATION AT CLOSING IN
AMOUNT OF $15.5 MILLION
* SIMULATIONS PLUS - FOLLOWING COMPLETION, IMMUNETRICS WILL
BE
WHOLLY-OWNED SUBSIDIARY OF SIMULATIONS PLUS, WILL CONTINUE TO
OPERATE UNDER IMMUNETRICS NAME
Source text for Eikon: ID:nBwbVFY30a
Further company coverage: SLP.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Simulations Plus
See all newsBrief: Simulations Plus Altaris To Pay $26 Million Termination Fee To Co If Merger Agreement Terminated
NASDAQ RESUMED AT 09:55 AM
Brief: Simulations Plus To Be Acquired By Altaris For Approximately $375 Million
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:55 AM
Simulations Plus Q2 results beat expectations but lowers annual profit forecast on tax rate jump